The Innovative Medicines Initiative (IMI) is a unique Public-Private Partnership (PPP) between the pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and associations (EFPIA), and the European Communities represented by the European Commission.

 

IMI's overall goal is to make Europe again the world leader in pharmaceutical research for the benefit of the economy and society, by removing research bottlenecks in the current drug development process.

 

For more information on the IMI, please visit http://imi.europa.eu/index_en.html.

 

The first Call for Proposals under the Innovative Medicines Initiative was released on 30 April 2008 at an official event in Brussels. Read the press release here.

 

IMI has a total budget of 2 billion Euros until 2013. In 2008 grants of around 123 million Euros will be awarded to the most promising research projects in the areas of brain disorders, metabolic and inflammatory diseases. In future calls IMI will also cover cancer and infectious diseases.

 

An information package for applicants can be downloaded here.